Molecular Pathology of Pancreatic Cancer: Implications for Molecular Targeting Therapy
Author:
- 1 November 2009
- journal article
- review article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (11) , S35-S39
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 33 references indexed in Scilit:
- Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cellsBiochemical and Biophysical Research Communications, 2008
- Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerGenes & Development, 2006
- Hedgehog/Ras interactions regulate early stages of pancreatic cancerGenes & Development, 2006
- AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancerOncogene, 2006
- Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreasLaboratory Investigation, 2005
- Abrogation of DUSP6 by hypermethylation in human pancreatic cancerJournal of Human Genetics, 2005
- Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cellsOncogene, 2003
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell, 1988
- Fine Structure of Three Major Grades of Malignancy of Human Pancreatic AdenocarcinomaPancreas, 1987